Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Oct;78(4):353–357. doi: 10.1136/hrt.78.4.353

Combination treatment with trimetazidine and diltiazem in stable angina pectoris

S Manchanda 1, S Krishnaswami 1
PMCID: PMC1892273  PMID: 9404250

Abstract

Objective—To assess antianginal efficacy and possible adverse haemodynamic effects of combination treatment with trimetazidine and diltiazem in patients with stable angina.
Design—Double blind, randomised, placebo controlled trial of four weeks duration.
Setting—Outpatient department of two Indian hospitals.
Subjects—64 male patients with stable angina, uncontrolled on diltiazem alone.
Interventions—Diltiazem 180 mg and trimetazidine 60 mg, or diltiazem 180 mg and placebo daily.
Main outcome measure—Change in exercise time to 1 mm ST segment depression.
Results—33 patients (55%) had no exercise induced angina at 3 mm ST segment depression at inclusion in the study (silent ischaemia). Intention to treat analysis showed that of 32 patients in each treatment group, the number (%) of patients responding to trimetazidine compared to placebo was: for anginal attacks, 28 (87.5) v 15 (46.9), p < 0.001; for exercise time to 1 mm ST segment depression, 21 (65.6) v 9 (28.1), p < 0.003; for exercise time to angina, 12 (37.5) v 5 (15.6), p < 0.05; and for maximum work at peak exercise, 17 (53.1) v 8 (25), p < 0.02. Compared to placebo, there was net improvement with trimetazidine in mean anginal attacks of 4.8/week (95% confidence interval (CI) 7.5 to 2.1; p < 0.002); in mean exercise times at 1 mm ST segment depression of 94.2 seconds (95% CI 182.8 to 5.6; p < 0.05), and at onset of angina of 113.1 seconds (95% CI 181.6 to 44.6; p < 0.02); and in mean maximum work at peak exercise of 1.4 metabolic equivalents (95% CI 2.4 to 0.3; p < 0.05).
Conclusions—Patients with stable angina uncontrolled with diltiazem had a clinically important improvement after combination treatment with trimetazidine, without adverse haemodynamic events or increased side effects.

 Keywords: trimetazidine;  diltiazem;  blood pressure;  stable angina;  treatment

Full Text

The Full Text of this article is available as a PDF (134.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

Mean anginal attacks and glyceryl trinitrate consumption according to study group:—— diltiazem + trimetazidine, - - - diltiazem + placebo. Bars represent 95% confidence intervals. *p < 0.05, †p < 0.01, difference in change from day 0 after treatment between the two groups.

Figure 2  .

Figure 2  

Open in a new tab

Mean treadmill exercise outcomes according to study group. —— diltiazem + trimetazidine, - - -  diltiazem + placebo. Bars represent 95% confidence intervals. Mets, metabolic equivalents. *p < 0.05, difference in change from day 0 after treatment between the two groups.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akhras F., Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet. 1991 Oct 26;338(8774):1036–1039. doi: 10.1016/0140-6736(91)91900-f. [DOI] [PubMed] [Google Scholar]
  2. BRUCE R. A., BLACKMON J. R., JONES J. W., STRAIT G. EXERCISING TESTING IN ADULT NORMAL SUBJECTS AND CARDIAC PATIENTS. Pediatrics. 1963 Oct;32:SUPPL–756. [PubMed] [Google Scholar]
  3. Bricaud H., Brottier L., Barat J. L., Combe C., Boussens B., Bonnet J. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drugs Ther. 1990 Aug;4 (Suppl 4):861–865. doi: 10.1007/BF00051293. [DOI] [PubMed] [Google Scholar]
  4. Dalla-Volta S., Maraglino G., Della-Valentina P., Viena P., Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990 Aug;4 (Suppl 4):853–859. doi: 10.1007/BF00051292. [DOI] [PubMed] [Google Scholar]
  5. Detry J. M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994 Mar;37(3):279–288. doi: 10.1111/j.1365-2125.1994.tb04276.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fabiani J. N., Ponzio O., Emerit I., Massonet-Castel S., Paris M., Chevalier P., Jebara V., Carpentier A. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992 Jul-Aug;33(4):486–491. [PubMed] [Google Scholar]
  7. Gevers W. Generation of protons by metabolic processes in heart cells. J Mol Cell Cardiol. 1977 Nov;9(11):867–874. doi: 10.1016/s0022-2828(77)80008-4. [DOI] [PubMed] [Google Scholar]
  8. Kober G., Buck T., Sievert H., Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992 Aug;13(8):1109–1115. doi: 10.1093/oxfordjournals.eurheartj.a060322. [DOI] [PubMed] [Google Scholar]
  9. Lazar E. J., Frishman W. H. Profile of an ideal antianginal agent. Drugs. 1989;38 (Suppl 2):1–8. doi: 10.2165/00003495-198900382-00003. [DOI] [PubMed] [Google Scholar]
  10. Maridonneau-Parini I., Harpey C. Trimetazidine protects the human red blood cell against oxygen free radical damage. Cardiovasc Drugs Ther. 1990 Aug;4 (Suppl 4):818–819. doi: 10.1007/BF00051284. [DOI] [PubMed] [Google Scholar]
  11. Maupoil V., Rochette L., Tabard A., Clauser P., Harpey C. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv Exp Med Biol. 1990;264:373–376. doi: 10.1007/978-1-4684-5730-8_58. [DOI] [PubMed] [Google Scholar]
  12. McCord J. M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985 Jan 17;312(3):159–163. doi: 10.1056/NEJM198501173120305. [DOI] [PubMed] [Google Scholar]
  13. McMurray J., Rankin A. Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris. BMJ. 1994 Nov 19;309(6965):1343–1350. doi: 10.1136/bmj.309.6965.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Opie L. H. Myocardial ischemia--metabolic pathways and implications of increased glycolysis. Cardiovasc Drugs Ther. 1990 Aug;4 (Suppl 4):777–790. doi: 10.1007/BF00051275. [DOI] [PubMed] [Google Scholar]
  15. Rao G. H., White J. G. Coronary artery disease: an overview of risk factors. Indian Heart J. 1993 May-Jun;45(3):143–153. [PubMed] [Google Scholar]
  16. Rossi A., Lavanchy N., Martin J. Antiischemic effects of trimetazidine: 31P-NMR spectroscopy study in the isolated rat heart. Cardiovasc Drugs Ther. 1990 Aug;4 (Suppl 4):812–813. doi: 10.1007/BF00051281. [DOI] [PubMed] [Google Scholar]
  17. Sellier P., Audouin P., Payen B., Corona P., Duong T. C., Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol. 1987;33(2):205–207. doi: 10.1007/BF00544569. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES